BeiGene gets CFDA approval to begin clinical trials with BGB-283 to treat solid tumors
The trials will investigate BGB-283 in patients with B-RAF mutations in a range of tumors where no other effective targeted therapies are currently available in China. In addition,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.